Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Stage-specific sensitivity to p53 restoration during lung cancer progression.

Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T.

Nature. 2010 Nov 25;468(7323):572-5. doi: 10.1038/nature09535.

2.

Selective activation of p53-mediated tumour suppression in high-grade tumours.

Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP.

Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526.

3.

Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Meylan E, Dooley AL, Feldser DM, Shen L, Turk E, Ouyang C, Jacks T.

Nature. 2009 Nov 5;462(7269):104-7. doi: 10.1038/nature08462. Epub 2009 Oct 21.

4.

Restoration of p53 function leads to tumour regression in vivo.

Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T.

Nature. 2007 Feb 8;445(7128):661-5. Epub 2007 Jan 24.

PMID:
17251932
5.

Suppression of lung adenocarcinoma progression by Nkx2-1.

Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T.

Nature. 2011 May 5;473(7345):101-4. doi: 10.1038/nature09881. Epub 2011 Apr 6.

6.

p53 suppresses carcinoma progression by inhibiting mTOR pathway activation.

Akeno N, Miller AL, Ma X, Wikenheiser-Brokamp KA.

Oncogene. 2015 Jan 29;34(5):589-99. doi: 10.1038/onc.2013.589. Epub 2014 Jan 27.

7.

Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer.

Mallakin A, Sugiyama T, Taneja P, Matise LA, Frazier DP, Choudhary M, Hawkins GA, D'Agostino RB Jr, Willingham MC, Inoue K.

Cancer Cell. 2007 Oct;12(4):381-94.

8.

TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis.

Shai A, Dankort D, Juan J, Green S, McMahon M.

Cancer Res. 2015 Aug 1;75(15):3167-80. doi: 10.1158/0008-5472.CAN-14-3701. Epub 2015 May 22.

9.

[Expression of protein p53 in the adenoma-colorectal carcinoma sequence].

Gafà R, Lanza G.

Pathologica. 1998 Aug;90(4):351-6. Italian.

PMID:
9793394
10.
11.

NKX2-1-mediated p53 expression modulates lung adenocarcinoma progression via modulating IKKβ/NF-κB activation.

Chen PM, Wu TC, Cheng YW, Chen CY, Lee H.

Oncotarget. 2015 Jun 10;6(16):14274-89.

12.

miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Kasinski AL, Slack FJ.

Cancer Res. 2012 Nov 1;72(21):5576-87. doi: 10.1158/0008-5472.CAN-12-2001. Epub 2012 Sep 10.

15.

Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.

Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA.

Genes Dev. 2003 Feb 15;17(4):488-501.

16.

A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.

Okada N, Lin CP, Ribeiro MC, Biton A, Lai G, He X, Bu P, Vogel H, Jablons DM, Keller AC, Wilkinson JE, He B, Speed TP, He L.

Genes Dev. 2014 Mar 1;28(5):438-50. doi: 10.1101/gad.233585.113. Epub 2014 Feb 14.

17.

Molecular pathogenesis of transplacentally induced mouse lung tumors.

Miller MS, Leone-Kabler S, Rollins LA, Wessner LL, Fan M, Schaeffer DO, McEntee MF, O'Sullivan MG.

Exp Lung Res. 1998 Jul-Aug;24(4):557-77. Review.

PMID:
9659583
18.

Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas.

Kanavaros P, Stefanaki K, Valassiadou K, Vlachonikolis J, Mavromanolakis M, Vlychou M, Kakolyris S, Gorgoulis V, Tzardi M, Georgoulias V.

Med Oncol. 1999 Apr;16(1):23-30.

PMID:
10382939
20.

The differential effects of mutant p53 alleles on advanced murine lung cancer.

Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, Jacks T.

Cancer Res. 2005 Nov 15;65(22):10280-8.

Supplemental Content

Support Center